JP2005502357A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005502357A5 JP2005502357A5 JP2003527090A JP2003527090A JP2005502357A5 JP 2005502357 A5 JP2005502357 A5 JP 2005502357A5 JP 2003527090 A JP2003527090 A JP 2003527090A JP 2003527090 A JP2003527090 A JP 2003527090A JP 2005502357 A5 JP2005502357 A5 JP 2005502357A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- cells
- medium
- culture
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 42
- 241000700605 Viruses Species 0.000 claims 28
- 208000015181 infectious disease Diseases 0.000 claims 10
- 239000002609 medium Substances 0.000 claims 10
- 230000012010 growth Effects 0.000 claims 7
- 238000004113 cell culture Methods 0.000 claims 6
- 239000012141 concentrate Substances 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 239000001963 growth medium Substances 0.000 claims 4
- 239000012092 media component Substances 0.000 claims 4
- 239000012737 fresh medium Substances 0.000 claims 3
- 238000000746 purification Methods 0.000 claims 3
- 241001529453 unidentified herpesvirus Species 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 241000702263 Reovirus sp. Species 0.000 claims 2
- 238000004115 adherent culture Methods 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000000032 diagnostic agent Substances 0.000 claims 2
- 229940039227 diagnostic agent Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004114 suspension culture Methods 0.000 claims 2
- 241000701161 unidentified adenovirus Species 0.000 claims 2
- 241000712891 Arenavirus Species 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- 241000701157 Canine mastadenovirus A Species 0.000 claims 1
- 208000037404 Central European encephalitis Diseases 0.000 claims 1
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 241000725619 Dengue virus Species 0.000 claims 1
- 241000709661 Enterovirus Species 0.000 claims 1
- 241000991587 Enterovirus C Species 0.000 claims 1
- 241000710831 Flavivirus Species 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
- 241000710842 Japanese encephalitis virus Species 0.000 claims 1
- 241000712079 Measles morbillivirus Species 0.000 claims 1
- 241000711386 Mumps virus Species 0.000 claims 1
- 241000709664 Picornaviridae Species 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010037742 Rabies Diseases 0.000 claims 1
- 241000702670 Rotavirus Species 0.000 claims 1
- 241000710799 Rubella virus Species 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 claims 1
- 208000004006 Tick-borne encephalitis Diseases 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 241000710772 Yellow fever virus Species 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 241001492478 dsDNA viruses, no RNA stage Species 0.000 claims 1
- 241001493065 dsRNA viruses Species 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000012533 medium component Substances 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 230000010412 perfusion Effects 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 241001147420 ssDNA viruses Species 0.000 claims 1
- 239000006228 supernatant Substances 0.000 claims 1
- 238000005199 ultracentrifugation Methods 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 229940051021 yellow-fever virus Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10144903A DE10144903A1 (de) | 2001-09-12 | 2001-09-12 | Vermehrung von Viren in Zellkultur |
| PCT/EP2002/010207 WO2003023025A1 (de) | 2001-09-12 | 2002-09-11 | Vermehrung von viren in zellkultur |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010145663A Division JP2010246559A (ja) | 2001-09-12 | 2010-06-25 | 細胞培養物中のウイルス増殖 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005502357A JP2005502357A (ja) | 2005-01-27 |
| JP2005502357A5 true JP2005502357A5 (enExample) | 2006-01-05 |
Family
ID=7698761
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003527090A Pending JP2005502357A (ja) | 2001-09-12 | 2002-09-11 | 細胞培養物中のウイルス増殖 |
| JP2010145663A Pending JP2010246559A (ja) | 2001-09-12 | 2010-06-25 | 細胞培養物中のウイルス増殖 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010145663A Pending JP2010246559A (ja) | 2001-09-12 | 2010-06-25 | 細胞培養物中のウイルス増殖 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20050118698A1 (enExample) |
| EP (1) | EP1427817B1 (enExample) |
| JP (2) | JP2005502357A (enExample) |
| KR (1) | KR100968141B1 (enExample) |
| AT (1) | ATE466932T1 (enExample) |
| AU (1) | AU2002338666B2 (enExample) |
| BR (1) | BR0212469A (enExample) |
| CA (1) | CA2456561A1 (enExample) |
| CY (1) | CY1110716T1 (enExample) |
| DE (2) | DE10144903A1 (enExample) |
| DK (1) | DK1427817T3 (enExample) |
| ES (1) | ES2345606T3 (enExample) |
| NZ (1) | NZ532203A (enExample) |
| PT (1) | PT1427817E (enExample) |
| SI (1) | SI1427817T1 (enExample) |
| WO (1) | WO2003023025A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ551640A (en) * | 2004-05-20 | 2010-05-28 | Id Biomedical Corp | Process for the production of an influenza vaccine |
| EP2578229B1 (en) | 2004-09-09 | 2013-07-10 | Novartis Vaccines and Diagnostics GmbH | Decreasing potential iatrogenic risks associated with vaccine antigens |
| CN101365480B (zh) | 2005-11-01 | 2014-11-05 | 诺华疫苗和诊断有限两合公司 | 经由β-丙内酯处理的残留细胞DNA水平降低的细胞衍生病毒疫苗 |
| HUE051122T2 (hu) | 2005-11-04 | 2021-03-01 | Seqirus Uk Ltd | Sejttenyészetben növesztett influenzavírusból elõállított nemvirion anti-géneket tartalmazó adjuvált vakcinák |
| WO2007052058A1 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
| EA014028B1 (ru) | 2005-11-04 | 2010-08-30 | Новартис Вэксинс Энд Диагностикс Срл | Эмульсии, содержащие свободное поверхностно-активное вещество в водной фазе в качестве адъюванта сплит вакцин против гриппа |
| AU2006310163B2 (en) | 2005-11-04 | 2011-09-15 | Seqirus UK Limited | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant |
| NZ592713A (en) | 2005-11-04 | 2012-12-21 | Novartis Vaccines & Diagnostic | Adjuvanted influenza vaccines including a cytokine-inducing agents other than an agonist of Toll-Like Receptor 9 |
| CN101448523A (zh) | 2006-03-24 | 2009-06-03 | 诺华疫苗和诊断有限两合公司 | 无需冷藏储存流感疫苗 |
| GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
| EP4585610A3 (en) * | 2006-09-11 | 2025-09-24 | Seqirus UK Limited | Making influenza virus vaccines without using eggs |
| EP2069480B1 (en) | 2006-09-15 | 2014-03-19 | MedImmune, LLC | Mdck cell lines supporting viral growth to high titers and bioreactor process using the same |
| CN101784283A (zh) | 2007-06-27 | 2010-07-21 | 诺华有限公司 | 低添加流感疫苗 |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| CN103952376A (zh) | 2008-09-24 | 2014-07-30 | 米迪缪尼有限公司 | 培养细胞、增殖和纯化病毒的方法 |
| JP5548207B2 (ja) | 2008-09-24 | 2014-07-16 | メディミューン，エルエルシー | ウイルスの精製方法 |
| WO2010052214A2 (en) | 2008-11-05 | 2010-05-14 | Glaxosmithkline Biologicals S.A. | Novel method |
| CN102548577A (zh) | 2009-04-27 | 2012-07-04 | 诺华有限公司 | 用于抵抗流感的佐剂疫苗 |
| JP5871806B2 (ja) * | 2009-10-20 | 2016-03-01 | ノバルティス アーゲー | ウイルスレスキューのための改善された逆遺伝学 |
| BR112012026095A2 (pt) | 2010-04-14 | 2015-09-15 | Emd Millipore Corp | métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos. |
| EP2566323A2 (en) | 2010-05-06 | 2013-03-13 | Novartis AG | Organic peroxide compounds for microorganism inactivation |
| EP2571520B1 (en) | 2010-05-21 | 2018-04-04 | Seqirus UK Limited | Influenza virus reassortment method |
| AU2011262309B2 (en) | 2010-06-01 | 2015-08-13 | Seqirus UK Limited | Concentration of influenza vaccine antigens without lyophilization |
| AU2011262312B2 (en) | 2010-06-01 | 2015-05-28 | Novartis Ag | Concentration and lyophilization of influenza vaccine antigens |
| US9517205B2 (en) | 2010-08-20 | 2016-12-13 | Seqirus UK Limited | Soluble needle arrays for delivery of influenza vaccines |
| CN103370077B (zh) * | 2011-02-17 | 2016-10-26 | 贝林格尔.英格海姆维特梅迪卡有限公司 | 猪繁殖与呼吸综合征病毒的商业化规模生产方法 |
| US9879229B2 (en) | 2011-03-14 | 2018-01-30 | National Research Council Of Canada | Method of viral production in cells |
| GB201216121D0 (en) | 2012-09-10 | 2012-10-24 | Novartis Ag | Sample quantification by disc centrifugation |
| CA2866465A1 (en) | 2012-03-06 | 2013-09-12 | Crucell Holland B.V. | Improved vaccination against influenza |
| US20150210986A1 (en) * | 2012-08-24 | 2015-07-30 | Ge Healthcare Bio-Sciences Corp. | Virus purification and formulation process |
| KR101370512B1 (ko) | 2013-06-07 | 2014-03-06 | 재단법인 목암생명공학연구소 | 무단백 배지에서 부유 배양되는 mdck 유래 세포주 및 상기 세포주를 이용하여 바이러스를 증식시키는 방법 |
| BR112017028011A2 (pt) | 2015-06-26 | 2018-08-28 | Seqirus Uk Ltd | vacinas de gripe correspondentes antigenicamente |
| CN108027371B (zh) | 2015-07-07 | 2020-08-18 | 思齐乐 | 流感效力试验 |
| CN105561317B (zh) * | 2015-12-22 | 2018-03-20 | 肇庆大华农生物药品有限公司 | 重组伪狂犬病病毒疫苗耐热冻干保护剂及其制备方法 |
| CN108239619A (zh) * | 2016-12-23 | 2018-07-03 | 甘肃健顺生物科技有限公司 | 悬浮mdck细胞相关疫苗生产的二阶培养工艺技术 |
| CN108570454A (zh) * | 2017-11-09 | 2018-09-25 | 甘肃健顺生物科技有限公司 | Mdbk驯化悬浮方法和二阶病毒生产工艺 |
| CN108570445A (zh) * | 2017-11-09 | 2018-09-25 | 甘肃健顺生物科技有限公司 | Pk15细胞驯化悬浮方法和二阶病毒生产工艺 |
| CN108570444A (zh) * | 2017-11-09 | 2018-09-25 | 甘肃健顺生物科技有限公司 | St细胞驯化悬浮方法和二阶病毒生产工艺 |
| MX2022006005A (es) | 2019-11-18 | 2022-10-27 | Seqirus Pty Ltd | Metodo para producir virus de la influenza reagrupados. |
| KR102444684B1 (ko) * | 2020-04-29 | 2022-09-16 | 에스케이바이오사이언스(주) | 일회용 배양 공정 시스템을 이용한 인플루엔자 바이러스 생산 방법 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19612966B4 (de) * | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| EP0878541A4 (en) * | 1996-10-18 | 2001-10-17 | Univ Osaka Res Found | ROTAVIRUS ANTIGENS, VACCINALS AND MEDICATIONS AGAINST INFECTION BY ROTAVIRUS, AND METHOD FOR THEIR PRODUCTION |
| GB9915413D0 (en) * | 1999-07-01 | 1999-09-01 | Glaxo Group Ltd | Propagation method |
| DE60142506D1 (de) * | 2000-03-03 | 2010-08-19 | Chemo Sero Therapeut Res Inst | In serumfreier kultur verwendbare zelle, kultursuspension und verfahren zur virusproduktion als impfstoff unter verwendung der zelle |
-
2001
- 2001-09-12 DE DE10144903A patent/DE10144903A1/de not_active Ceased
-
2002
- 2002-09-11 EP EP02777068A patent/EP1427817B1/de not_active Expired - Lifetime
- 2002-09-11 AT AT02777068T patent/ATE466932T1/de active
- 2002-09-11 SI SI200230909T patent/SI1427817T1/sl unknown
- 2002-09-11 PT PT02777068T patent/PT1427817E/pt unknown
- 2002-09-11 AU AU2002338666A patent/AU2002338666B2/en not_active Ceased
- 2002-09-11 JP JP2003527090A patent/JP2005502357A/ja active Pending
- 2002-09-11 WO PCT/EP2002/010207 patent/WO2003023025A1/de not_active Ceased
- 2002-09-11 DK DK02777068.4T patent/DK1427817T3/da active
- 2002-09-11 BR BR0212469-6A patent/BR0212469A/pt not_active IP Right Cessation
- 2002-09-11 NZ NZ532203A patent/NZ532203A/en not_active IP Right Cessation
- 2002-09-11 US US10/487,709 patent/US20050118698A1/en not_active Abandoned
- 2002-09-11 ES ES02777068T patent/ES2345606T3/es not_active Expired - Lifetime
- 2002-09-11 DE DE50214416T patent/DE50214416D1/de not_active Expired - Lifetime
- 2002-09-11 KR KR1020047003711A patent/KR100968141B1/ko not_active Expired - Lifetime
- 2002-09-11 CA CA002456561A patent/CA2456561A1/en not_active Abandoned
-
2010
- 2010-06-25 JP JP2010145663A patent/JP2010246559A/ja active Pending
- 2010-07-30 CY CY20101100718T patent/CY1110716T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005502357A5 (enExample) | ||
| JP2005532779A5 (enExample) | ||
| CA2455189A1 (en) | Methods for producing an active constituent of a pharmaceutical or a diagnostic agent in an mdck cell suspension culture | |
| ES2335395T3 (es) | Metodo mejorado para la produccion a escala de antigenos virales. | |
| JP2009034115A5 (enExample) | ||
| JP2010138205A5 (enExample) | ||
| KR20030032923A (ko) | 무혈청 배양 및 부유 배양에서 사용할 수 있는 세포 및상기 세포를 사용하여 백신용 바이러스를 제조하는 방법 | |
| JP2005502357A (ja) | 細胞培養物中のウイルス増殖 | |
| TW201311896A (zh) | 製備病毒抗原及疫苗之方法 | |
| ES2733489T3 (es) | Proceso de purificación de poliovirus a partir de cultivos celulares | |
| JP2013515473A5 (enExample) | ||
| IL190578A (en) | A viro cell line and a method to create a virus to prepare vaccines from it | |
| US20220267738A1 (en) | Method For Purifying An Enveloped Virus | |
| CN110268052A (zh) | 纯化病毒的方法 | |
| EP2155863B1 (en) | Two-step temperature profile for the propagation of viruses | |
| CN1470641A (zh) | 一种用于筛选和评价抗hcv药物的方法及其应用 | |
| HK1137780B (en) | Two-step temperature profile for the propagation of viruses |